Klinik für Augenheilkunde, Universitätsklinikum Münster, Deutschland.
Klin Monbl Augenheilkd. 2021 Jan;238(1):48-54. doi: 10.1055/a-1274-0773. Epub 2021 Jan 27.
The LacriJet (FCI S. A. S. - France Chirurgie Instrumentation, Paris, France) represents a novel, simplified and preloaded system for monocanalicular or monocanaliculonasal nasolacrimal duct intubation. It is a further development of the Masterka and shall reduce the intubation time during the surgical procedure. The aim of the present study was to present first experiences with this system for different indications.
All patients who underwent nasolacrimal duct intubation with the LacriJet at the University of Muenster Medical Center in the period from March to November 2019 were included. The postoperative outcome was evaluated 3 to 6 months later.
In total, 12 nasolacrimal duct intubations with the LacriJet were performed at our center in the above-mentioned period. The main indication for intubation was congenital nasolacrimal duct obstruction (CNLDO). In addition, intubation was performed in cases with eye lid tumors involving the nasolacrimal duct, in a case of canalicular laceration and in a case of canaliculitis. In 3 cases, there was an early dislocation or a complete loss of intubation. Of these, 2 were cases with CNLDO and the third dislocation was due to manipulation by the patient. All in all, the functional results were satisfying.
The use of the LacriJet is highly suitable for the treatment of CNLDO, stenting in canalicular laceration or lid tumours involving the lacrimal drainage system. However, the known disadvantages of monocanalicular intubation (dislocation, early loss of intubation) also occur with this type of system and a system briefing seems useful. The LacriJet therefore represents a modern and simple method for nasolacrimal duct intubation and can be used for various indications.
LacriJet（法国 FCI S. A. S. - 法国 Chirurgie Instrumentation，巴黎，法国）是一种新颖、简化且预加载的单通道或单通道鼻内鼻泪管插管系统。它是 Masterka 的进一步发展，可减少手术过程中的插管时间。本研究旨在介绍该系统在不同适应证中的初步经验。
纳入 2019 年 3 月至 11 月期间在明斯特大学医学中心接受 LacriJet 鼻泪管插管的所有患者。术后 3 至 6 个月后评估术后结果。
在上述期间，我们中心共进行了 12 例 LacriJet 鼻泪管插管。插管的主要适应证为先天性鼻泪管阻塞（CNLDO）。此外，还对累及鼻泪管的眼睑肿瘤、泪小管裂伤和泪小管炎进行了插管。有 3 例早期脱位或完全失去插管。其中 2 例为 CNLDO，第 3 例脱位是由于患者的操作所致。所有这些病例的功能结果均令人满意。
LacriJet 非常适合治疗 CNLDO、泪小管裂伤的支架置入或累及泪道系统的眼睑肿瘤。然而，这种单通道插管的已知缺点（脱位、早期失去插管）也会发生在这种类型的系统中，因此系统介绍似乎很有用。因此，LacriJet 是一种用于鼻泪管插管的现代而简单的方法，可用于各种适应证。
